Aloin(Synonyms: 芦荟素; Aloin-A; Barbaloin-A)

发表于2024年10月18日由上海金畔生物科技有限公司

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Aloin (Synonyms: 芦荟素; Aloin-A; Barbaloin-A) 纯度: 98.32%

Aloin(Aloin-A; Barbaloin-A)是一天然抗肿瘤蒽醌苷，具有铁螯合活性。

Aloin Chemical Structure

CAS No. : 1415-73-2

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥500	In-stock
50 mg	￥400	In-stock
100 mg	￥600	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

Aloin 相关产品

•相关化合物库:

Natural Product Library Plus
Bioactive Compound Library Plus
Natural Product Library
Anti-Cancer Compound Library
Phenols Library
Traditional Chinese Medicine Monomer Library
FDA Approved & Pharmacopeial Drug Library

生物活性

Aloin(Aloin-A; Barbaloin-A) is a natural antitumor anthraquinone glycoside with iron chelating and non-atherogenic activities. IC50 value: Target: in vitro: Aloin significantly inhibited HUVECs proliferation, migration and tube formation in vitro. suppressed activation of VEGF receptor (VEGFR) 2 and STAT3 phosphorylation in endothelial cells. In addition, the constitutively activated STAT3 protein, and the expression of STAT3-regulated antiapoptotic (Bcl-xL), proliferative (c-Myc), and angiogenic (VEGF) proteins were also down-regulated in response to AL in human SW620 cancer cells [1]. aloin exerted inhibition of cell proliferation, adhesion and invasion abilities of B16-F10 melanoma cells under non-cytotoxic concentrations. Furthermore, aloin induced melanoma cell differentiation through the enhancement of melanogenesis and transglutaminase activity [2]. in vivo: Aloin substantially reduced tumor volumes and weight in vivo mouse xenografts, without obviously toxicity [1]. Aloin (10, 30 mg/kg bw) or vehicle was given by gavage to mice after each alcohol administration. Alcohol elevated the serum transaminases alanine aminotransferase, aspartate aminotransferase, total cholesterol and triglyceride levels which were significantly attenuated by the co-administration of aloin (p < 0.05) [3].

分子量

418.39

Formula

C₂₁H₂₂O₉

CAS 号

1415-73-2

中文名称

芦荟甙；芦荟素；巴白洛英；坝巴甙；芦荟素A；芦荟苷A

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL (298.76 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3901 mL	11.9506 mL	23.9011 mL
5 mM	0.4780 mL	2.3901 mL	4.7802 mL
10 mM	0.2390 mL	1.1951 mL	2.3901 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.97 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.97 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.97 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Pan Q, et al. Inhibition of the angiogenesis and growth of Aloin in human colorectal cancer in vitro and in vivo. Cancer Cell Int. 2013 Jul 12;13(1):69.

[2]. Tabolacci C, et al. Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation. Amino Acids. 2013 Jan;44(1):293-300.

[3]. Cui Y, et al. Aloin protects against chronic alcoholic liver injury via attenuating lipid accumulation, oxidative stress and inflammation in mice. Arch Pharm Res. 2014 Dec;37(12):1624-33.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

英国Electrothermal V型塑料外壳电加热套EMV1000/CE

发表于2024年10月18日由上海金畔生物科技有限公司

【简单介绍】

英国Electrothermal V型塑料外壳电加热套EMV1000/CE，采用化学防腐聚丙烯外壳，可以容纳60°锥型漏斗、梨形和圆底烧瓶。多种尺寸的烧瓶和漏斗都可容纳，更多灵活性。有一个不锈钢保护屏覆盖在加热元件上方，保护您在液体溅射和烧瓶破裂时免受电击。
！

【详细说明】

英国Electrothermal V型塑料外壳电加热套EMV1000/CE

产品描述：

英国Electrothermal V型塑料外壳电加热套EMV1000/CE可以容纳60°锥型漏斗、梨形和圆底烧瓶。多种尺寸的烧瓶和漏斗都可容纳，更多灵活性。有一个不锈钢保护屏覆盖在加热元件上方，保护您在液体溅射和烧瓶破裂时免受电击。

主要特点:

底座开口，可容纳60°锥型漏斗、梨形和圆底烧瓶
可容纳大型的烧瓶/漏斗，容量在10ml-5L之间
盘绕的加热元件悬挂在一个隔热盒中，提供佳的热传递和支撑
“Cool-to-the-touch”凉外壳技术
加热元件温度可达450℃
内置功率调节器
配有电源和加热指示灯
可更换独立加热盘
化学防腐聚丙烯外壳
接地保护屏和双保险管等更多安全措施
适合13cm直径支撑杆的固定夹（但不包含支撑杆）

技术指标

EMV/ EMX 型号	EMV0050, EMV0100, EMV0250	EMV1000, EMX1000	EMV5000, EMX5000
烧瓶/漏斗容量	10 – 250ml	500 – 1000ml	2000- 5000ml
材质	聚丙烯外壳	聚丙烯外壳	聚丙烯外壳
大元件温度	450°C	450°C	450°C
尺寸 (d x w x h), mm	260 x 175 x 127	310 x 238 x 145	400 x 350 x 190
运输重量, kg	0.78	2.76	5.96

订货信息

型号	容量	电源
EMV0050/CE	10 to 50ml	230V 50/60Hz, 60W
EMV0050/CEX1	10 to 50ml	115V 50/60Hz, 70W
EMV0050/CEX6*	10 to 50ml	230V 50/60Hz, 60W
EMV0250/CE	100 to 250ml	230V 50/60Hz, 150W
EMV0250/CEX1	100 to 250ml	115V 50/60Hz, 150W
EMV0250/CEX6*	100 to 250ml	230V 50/60Hz, 150W
EMV1000/CE	500 to 1000ml	230V 50/60Hz, 300W
EMV1000/CEX1	500 to 1000ml	115V 50/60Hz, 300W
EMV1000/CEX6*	500 to 1000ml	230V 50/60Hz, 300W
EMV5000/CE	2000 to 5000ml	230V 50/60Hz, 800W
EMV5000/CEX1	2000 to 5000ml	115V 50/60Hz, 800W
EMV5000/CEX6*	2000 to 5000ml	230V 50/60Hz, 800W

*附带EU欧洲插头

Tauroursodeoxycholate sodium(Synonyms: 牛磺熊去氧胆酸钠; Tauroursodeoxycholic acid sodium; TUDCA sodium; UR 906 sodium)

发表于2024年10月18日由上海金畔生物科技有限公司

Tauroursodeoxycholate sodium (Synonyms: 牛磺熊去氧胆酸钠; Tauroursodeoxycholic acid sodium; TUDCA sodium; UR 906 sodium) 纯度: 98.63%

Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium 是一种内质网应激抑制剂。Tauroursodeoxycholate 显著降低凋亡分子如 caspase-3 和 caspase-12 表达。Tauroursodeoxycholate 也抑制 ERK。

Tauroursodeoxycholate sodium Chemical Structure

CAS No. : 35807-85-3

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥825	In-stock
100 mg	￥750	In-stock
500 mg	￥1500	In-stock
1 g		询价
5 g		询价

* Please select Quantity before adding items.

Tauroursodeoxycholate sodium 相关产品

•相关化合物库:

Drug Repurposing Compound Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Immunology/Inflammation Compound Library
Kinase Inhibitor Library
MAPK Compound Library
Metabolism/Protease Compound Library
Stem Cell Signaling Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Human Endogenous Metabolite Compound Library
Anti-Aging Compound Library
Drug Repurposing Compound Library
Reprogramming Compound Library
Oxygen Sensing Compound Library
Endoplasmic Reticulum Stress Compound Library
Pyroptosis Compound Library
Glutamine Metabolism Compound Library
Neurodegenerative Disease-related Compound Library
Angiogenesis Related Compound Library
Food-Sourced Compound Library
Anti-Liver Cancer Compound Library
Rare Diseases Drug Library
Anti-Colorectal Cancer Compound Library

生物活性

Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

IC₅₀ & Target^[1]^[2]

ERK

Caspase-3

Caspase-12

体外研究
(In Vitro)

Tauroursodeoxycholate (TUDCA) suppresses both viability and migration of vascular smooth muscle cells (VSMCs) through inhibition of ERK phosphorylation, by induction of mitogen-activated protein kinase phosphatase-1 (MKP-1) via PKCα. Tauroursodeoxycholate inhibits both the proliferation and migration of VSMCs via inhibition of ERK, through Ca²⁺-dependent PKCα translocation. Tauroursodeoxycholate prevents platelet-derived growth factor (PDGF) and vascular injury-induced MMP-9 expression. The knock-down of MKP-1 using specific si-RNA restores the reduced VSMC viability by Tauroursodeoxycholate (200 μM), which suggests that anti-proliferative effect of Tauroursodeoxycholate depended on the MKP-1 expression^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

The effects of Tauroursodeoxycholate (TUDCA) on proliferation and apoptosis of VSMCs in vivo are examined using immunohistochemistry for proliferating cell nuclear antigen (PCNA) and the transferase dUTP nick-end labelling (TUNEL) assay. Tauroursodeoxycholate (10, 50, and 100 mg/kg) increases the caspase 3 activity of injured tissues in a dose-dependent manner, indicating that Tauroursodeoxycholate induces apoptosis of VSMCs in the neointima. Using the injured tissues, further examination and comparison of the phosphorylation level of ERK and MMP-9 expression is performed at 1 week after injury, compared with normal controls. Balloon injury increased both the phosphorylation of ERK and expression of MMP-9 in the tissues. Tauroursodeoxycholate (10, 50, and 100 mg/kg) inhibits phosphorylation of ERK and MMP-9 expression in a dose-dependent manner^[1]. Tauroursodeoxycholate (TUDCA) is a hydrophilic bile acid. Tauroursodeoxycholate as a cytoprotective agent improves liver function and can prevent hepatocellular carcinoma by reducing ER stress and apoptosis. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3, caspase-12, C/EBP homologous protein, c-Jun N-terminal kinase (JNK), activating transcription factor 4 (ATF4), X-box binding protein (XBP), and eukaryotic initiation factor 2α (eIF2α) in Ang II induced ApoE^-/- mice (p<0.05). Tauroursodeoxycholate reduces Angiotensin (Ang) II induced abdominal aortic aneurysm (AAA) formation in ApoE^-/- mice. Tauroursodeoxycholate is used at a dose of 0.5 g/kg/day in treating Ang II induced ApoE^-/- mice (ER stress inhibitor group). Systolic blood pressure (141.3±5.6 mmHg vs 145.9±8.9 mmHg; p>0.05) and total cholesterol levels (663.6±88.7 mg/dL vs 655.7±65.4 mg/dL; p>0 .05) do not differ between the AAA model group and Tauroursodeoxycholate group. In addition, maximum aortic diameter is significantly smaller in those in Tauroursodeoxycholate group compared with those in the AAA model group (0.95±0.03 mm vs 1.79±0.04 mm; p<0.05). AAA lesion areas are also smaller in those in Tauroursodeoxycholate group than in those in the AAA model group (0.37±0.03 mm² vs 1.51±0.06 mm²; p<0.05)^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

521.69

Formula

C₂₆H₄₄NNaO₆S

CAS 号

35807-85-3

中文名称

牛磺熊去氧胆酸钠；牛磺熊脱氧胆酸钠

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

H₂O : 100 mg/mL (191.68 mM; Need ultrasonic)

DMSO : 100 mg/mL (191.68 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9168 mL	9.5842 mL	19.1685 mL
5 mM	0.3834 mL	1.9168 mL	3.8337 mL
10 mM	0.1917 mL	0.9584 mL	1.9168 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： PBS

Solubility: 100 mg/mL (191.68 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.79 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.79 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.79 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.79 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16.

[2]. Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345.

Cell Assay ^[1]	Cell viability and proliferation are measured using Ez-Cytox. VSMCs (5×10³ cells) are seeded onto 96-well plates in Smooth Muscle Cell Growth Medium 2 (SMCGM2) and cultured. After serum starvation, Tauroursodeoxycholate (0, 50, 100, and 200 μM) is added to the hVSMCs, with or without 1,2-bis(o-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid tetra(acetoxymethyl) ester (BAPTA, 10 μM) and 7-hydroxystaurosporine (H7, 10 μM) and cultured for 24 h. To assess the effect of Tauroursodeoxycholate on the PDGF-stimulated hVSMC proliferation, hVSMCs are seeded onto 96-well plates and cultured. After serum starvation, Tauroursodeoxycholate (0, 50, 100, and 200 μM) is added to the hVSMCs, with or without PDGF-BB (50 ng/mL) and cultured. After addition of 10 μL of Ez-Cytox into each well, cell viability is evaluated by measuring the optical density at 450 nm^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]^[2]	Rats^[1] Sprague-Dawley rats are anaesthetized with a combined anaesthetic (Ketamine, 70 mg/kg; Xylazine, 7 mg/kg ip). Tauroursodeoxycholate is administered orally once a day, in different concentrations (i.e. vehicle, 10, 50, and 100 mg/kg) for 2 weeks. The carotid arteries are fixed by perfusion with 4% formaldehyde, then the tissues are embedded in paraffin, and sections (8 μm) are stained with H&E^[1]. Mice^[2] Thirty ApoE^-/- C57BL/6 male mice aged 8 weeks are randomly divided into three groups (n=10 in each group): (i) sham operated and injected with physiologic (0.9%) saline as vehicle (normal: group); (ii) mini-osmotic pumps are implanted subcutaneously into the right flank of ApoE^-/- mice to release Ang II (1000 ng/kg/min) over the course of 28 days (AAA model group); (iii) AAA model mice treated with Tauroursodeoxycholate daily for 4 weeks at a dosage of 0.5 g/kg/day in drinking water (Tauroursodeoxycholate group). Mice are sacrificed after 28 days of Ang II infusion^[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16. [2]. Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

上海沛欧红外石英程序升温20孔消化炉SKD-20S2(重金属消化炉)

发表于2024年10月18日由上海金畔生物科技有限公司

上海沛欧红外石英程序升温20孔消化炉SKD-20S2(重金属消化炉)

品牌沛欧|PEIOU

型号 SKD-20S2(重金属消化炉)

商品详情

仪器特点：

1 温度可控，杜绝消化挂壁现象，样品还原性好。
2、加热体（模块）采用红外石英管，耐强酸强碱、防爆裂，寿命长，符合CE标准
3、炉孔温度和升温速率连可调，升温速度快且杜绝挂壁

4、消化管受热面积大、温差小，样品消化一致性好，热效率高

5、仪器具有过流保护和漏电保护
6、采用双开关，电源和加热单独控制，便于安全参数设置，节约能源。
7、采用新一代数显控温仪，PID智能控制技术，控温精度高。

8、仪器有不锈钢排污罩，使消化管内逸出的SO2等有害气体，通过排污管经抽吸泵从水中排入下水道，有效地抑制有害气体的外逸，消化管，消化架，冷却架。(SKD-18S2/SKD-48S2/SKD-20T没有排污罩)

9、样品防爆器（选配）

型号	SKD-20S2
控制方式	单片机
加热方式	红外石英加热管
炉孔数量	20孔
控温范围	室温-680℃
升温速度	20分钟（400℃空载）
温度波动	±1℃
电压	AC220V
功率	1950W
消化管尺寸	42mm*300mm

选择消化炉注意事项

消化炉在蛋白质检测中起到了很重要的作用，选择一台合适的消化炉是准确检测的前提。消化炉指标要注意几点：

1 温度要恒定，波动要小，每批样品可以有一致的消化时间，

2 每一个样品孔温差要小，以免样品消化时间相差太大，引起消化差别。

3 能有效的控制温度变化的过程，以免消化时样品挂壁。

4 有效地保温措施，以提高炉腔内温度的恒定性

* 有效地温度控制，使得消化能按需要控制温度，如果有程序升温控制就能有效达到所需。

* 很好的保温措施，如果保温材料势单力薄，必造成温度不稳定。仪器较厚的保温层是温度稳定的需要。故保温材料的厚度和材质是一个重要的指标、

5 加热体和热载体的选择，可以根据用户的需要选择不同的热载体。下面我们来讨论加热体和热载体的选择。

*红外加热，靠热辐射来加热样品，特点是：升温快，热惯性小，温控准确。一般应用于有高要求样品的消化。例如：有较快的升温和降温速度。程序升温使用户，根据样品的特点来选择升温曲线，或选择分段式的升温，有利于样品的消化，从而减少样品挂壁现象、使得样品消化准确率大大提高

* 铝锭加热，靠铝锭传导热能给样品，特点：升温较慢，热惯性较大，温度较稳定，还由于铝锭的良好的热传导性，每个样品孔间的温度一致性好。广泛应用于消化炉的热载体，但也要注意：一片薄薄的铝锭也不能保持温度的恒定，所以选择铝锭消化炉，铝锭厚度也是一个考察指标。

*石墨加热，靠石墨传导给样品热量，特点：热惯性大，升温慢，由于石墨热传导性较差（相比较铝锭），使得样品孔间温度不均匀，容易造成样品间消化时间差拉大，一些样品消化时间太长，而另一些时间又太短。影响数据的准确性。但是由于石墨材料成本低（相对于铝锭），石墨消化炉成本便宜，对部分低端用户有一定的吸引力。进口凯氏消化炉没有采用石墨作为热传导的。

其余要注意消化炉的保护功能：加热控制和设置参数要区别控制，过流、漏电、短路保护。

以上罗列了一些选择消化炉注意事项，建议选购前，先了解自己的真实需求，别被低的价格所迷惑而招损。

Isoescin IB(Synonyms: 异七叶皂苷 IB)

发表于2024年10月18日由上海金畔生物科技有限公司

Isoescin IB (Synonyms: 异七叶皂苷 IB) 纯度: 95.23%

Isoescin IB 是 Escin IB 的异构体。Isoescin IB 和 Escin IB 是 Escin 中的主要活性成分。

Isoescin IB Chemical Structure

CAS No. : 219944-46-4

规格	价格	是否有货
5 mg	￥3430	In-stock
10 mg		询价
50 mg		询价

* Please select Quantity before adding items.

Isoescin IB 相关产品

•相关化合物库:

Natural Product Library Plus
Bioactive Compound Library Plus
Natural Product Library
Anti-Cancer Compound Library
Glycoside Compound Library
Terpenoids Library

生物活性

Isoescin IB is an isomer of Escin IB. Isoescin IB and Escin IB are the chief active ingredients in escin^[1].

体外研究
(In Vitro)

β-Escin (mainly consisting of escin Ia and escin Ib) is the major active ingredient in horse chestnut seeds extracts. β-escin can inhibit proliferation and/or induce apoptosis in various types of cancer cells including A549 cell, HT-29 cell, HCC cell, OVCAR3 cell and H-Ras 5RP7 cell. β-escin may be useful as a chemopreventive agent, especially for tumors associated with an inflammatory response^[1].
As the minor component of escin, α-escin (mainly consisting of isoescin Ia and isoescin Ib) exhibits lower bioactivity^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1131.26

Formula

C₅₅H₈₆O₂₄

CAS 号

219944-46-4

中文名称

异七叶皂苷 IB

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : 100 mg/mL (88.40 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.8840 mL	4.4199 mL	8.8397 mL
5 mM	0.1768 mL	0.8840 mL	1.7679 mL
10 mM	0.0884 mL	0.4420 mL	0.8840 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.21 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.21 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.21 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

参考文献

[1]. Wu XJ, et al. Comparative pharmacokinetics and the bioavailability of escin Ib and isoescin Ib following the administration of escin, pure escin Ib and isoescin Ib in rats.J Ethnopharmacol. 2014 Feb 3;151(2):839-45.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SJG-136(Synonyms: NSC-694501)

发表于2024年10月18日由上海金畔生物科技有限公司

SJG-136 (Synonyms: NSC-694501) 纯度: ≥98.0%

SJG-136 是一种有效的 DNA 交联剂 (DNA crosslinker)，与 pBR322 DNA 交联的 XL₅₀ 值为 45 nM。SJG-136 具有抗肿瘤作用。

SJG-136 Chemical Structure

CAS No. : 232931-57-6

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥6000	In-stock
1 mg	￥2800	In-stock
5 mg	￥4900	In-stock
10 mg	￥7400	In-stock
25 mg	￥14800	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

SJG-136 相关产品

•相关化合物库:

Drug Repurposing Compound Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
Toxins for Antibody-Drug Conjugate Research Library

生物活性

SJG-136 is a DNA cross-linking agent, with an XL₅₀ of 45 nM for pBR322 DNA. SJG-136 has potent antitumor activity.

IC₅₀ & Target

XL50: 45 nM (pBR322 DNA)^[1]

体外研究
(In Vitro)

SJG-136 (dimer 5) is a DNA cross-linking agent, with an XL₅₀ (concentration of agent required for 50% cross-linking of pBR322 DNA) of 45 nM for pBR322 DNA. SJG-136 is cytotoxic to ovarian cell lines, such as A2780 (IC₅₀, 22.5 pM), A2780cisR (IC₅₀, 24 pM), CH1 (IC₅₀, 0.12 nM), CH1cisR (IC₅₀, 0.6 nM), and SKOV-3 (IC₅₀, 9.1 nM)^[1]. SJG-136 (SG2000) also reduces the viability of a panel of canine cancer cells, with GI₅₀ values ranging from 0.33 – >100 nM after a 1 h exposure, and <0.03 - 17.33 nM following continuous exposure^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

SJG-136 shows more potent antitumor effect against CMeC-1 tumour at 0.30 mg/kg than 0.15 mg/kg either as a single dose or administered once a week for three weeks via dosed intravenously in mice. SJG-136-induced H2AX phosphorylation shows good correspondence, but less sensitivity, than measurement of foci^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

556.61

Formula

C₃₁H₃₂N₄O₆

CAS 号

232931-57-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 33.33 mg/mL (59.88 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.7966 mL	8.9830 mL	17.9659 mL
5 mM	0.3593 mL	1.7966 mL	3.5932 mL
10 mM	0.1797 mL	0.8983 mL	1.7966 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.49 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.49 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: 2.08 mg/mL (3.74 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (3.74 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.74 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.74 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Gregson SJ, et al. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem. 2001 Mar 1;44(5):737-48.

[2]. Mellinas-Gomez M, et al. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. BMC Vet Res. 2015 Aug 19;11:215.

Cell Assay ^[1]	In vitro cytotoxicity is evaluated using the human ovarian carcinoma cell lines SKOV-3, A2780, and CH1, together with the cisplatin-resistant counterparts of the A2780 and CH1 lines (A2780cisR and CH1cisR, respectively). Viable cells are seeded in growth medium (160 μL) into 96-well microtiter plates and allowed to attach overnight. SJG-136 is dissolved in DMSO (to give a 20 mM concentration in each case) immediately prior to adding to the cells in quadruplicate wells. Final drug concentrations in the wells ranged from 100 μM to 2.5 nM as follows: 100, 25, 10, 2.5, 1 μM, and 250, 100, 25, 10, 2.5 nM. This is achieved by diluting the drugs in growth medium and then adding 40 μL to the existing well volume of 160 μL to give the final concentrations stated above. After 4 days (96 h), the medium is removed and the remaining cells are fixed using 10% trichloroacetic acid on ice for 30 min. Wells are then washed 3−4 times with tap water and air-dried overnight, and 100 μL of 0.4% sulforhodamine B (dissolved in 1% glacial HOAc) is added to each well. Staining is allowed to continue for 10−15 min; the wells are then washed 3−4 times with 1% acetic acid and air-dried, and Tris base (100 μL of 10 mM) is added to each one. The plates are then shaken and absorbance readings taken at 540 nm using a plate reader. From plots of concentration versus percentage absorbance (compared to 8 untreated wells), IC₅₀ values are calculated using the Quattro-Pro software package^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	A homogenous suspension of 5 × 10⁶ exponentially growing canine melanoma cells in serum free RPMI 1640 tissue culture medium is injected subcutaneously into CD1 Nu/Nu immunocompromised female mice. The mice are divided into five groups of ten mice, with equivalent mean tumour volumes for each group. SJG-136 is given intravenously into the tail vein to four of these groups and vehicle control is administered to the fifth group. SJG-136 injections are prepared in 0.9 % NaCl and 1 % DMSO vehicle. Animals are weighed prior to the injection to determine the volume of SJG-136 required (0.1 mL/10 g body weight) which is given IV in the tail vein. Control group mice are given an IV injection of the vehicle solution; mice in groups one and two are given a single treatment of SJG-136, 0.15 mg/kg and 0.30 mg/kg respectively; mice in groups four and five are given 0.15 mg/kg and 0.30 mg/kg respectively, every seven days for a total of three treatments^[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Gregson SJ, et al. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J Med Chem. 2001 Mar 1;44(5):737-48. [2]. Mellinas-Gomez M, et al. Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours. BMC Vet Res. 2015 Aug 19;11:215.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

英国Electrothermal V型塑料外壳电加热套EMV0050/CE

发表于2024年10月18日由上海金畔生物科技有限公司

【简单介绍】

英国Electrothermal V型塑料外壳电加热套EMV0050/CE可以容纳60°锥型漏斗、梨形和圆底烧瓶。多种尺寸的烧瓶和漏斗都可容纳，更多灵活性。有一个不锈钢保护屏覆盖在加热元件上方，保护您在液体溅射和烧瓶破裂时免受电击。
！

【详细说明】

英国Electrothermal V型塑料外壳电加热套EMV0050/CE

产品描述：

英国Electrothermal V型塑料外壳电加热套EMV0050/CE可以容纳60°锥型漏斗、梨形和圆底烧瓶。多种尺寸的烧瓶和漏斗都可容纳，更多灵活性。有一个不锈钢保护屏覆盖在加热元件上方，保护您在液体溅射和烧瓶破裂时免受电击。

主要特点:

底座开口，可容纳60°锥型漏斗、梨形和圆底烧瓶
可容纳大型的烧瓶/漏斗，容量在10ml-5L之间
盘绕的加热元件悬挂在一个隔热盒中，提供佳的热传递和支撑
“Cool-to-the-touch”凉外壳技术
加热元件温度可达450℃
内置功率调节器
配有电源和加热指示灯
可更换独立加热盘
化学防腐聚丙烯外壳
接地保护屏和双保险管等更多安全措施
适合13cm直径支撑杆的固定夹（但不包含支撑杆）

技术指标

EMV/ EMX 型号	EMV0050, EMV0100, EMV0250	EMV1000, EMX1000	EMV5000, EMX5000
烧瓶/漏斗容量	10 – 250ml	500 – 1000ml	2000- 5000ml
材质	聚丙烯外壳	聚丙烯外壳	聚丙烯外壳
大元件温度	450°C	450°C	450°C
尺寸 (d x w x h), mm	260 x 175 x 127	310 x 238 x 145	400 x 350 x 190
运输重量, kg	0.78	2.76	5.96

订货信息

型号	容量	电源
EMV0050/CE	10 to 50ml	230V 50/60Hz, 60W
EMV0050/CEX1	10 to 50ml	115V 50/60Hz, 70W
EMV0050/CEX6*	10 to 50ml	230V 50/60Hz, 60W
EMV0250/CE	100 to 250ml	230V 50/60Hz, 150W
EMV0250/CEX1	100 to 250ml	115V 50/60Hz, 150W
EMV0250/CEX6*	100 to 250ml	230V 50/60Hz, 150W
EMV1000/CE	500 to 1000ml	230V 50/60Hz, 300W
EMV1000/CEX1	500 to 1000ml	115V 50/60Hz, 300W
EMV1000/CEX6*	500 to 1000ml	230V 50/60Hz, 300W
EMV5000/CE	2000 to 5000ml	230V 50/60Hz, 800W
EMV5000/CEX1	2000 to 5000ml	115V 50/60Hz, 800W
EMV5000/CEX6*	2000 to 5000ml	230V 50/60Hz, 800W

*附带EU欧洲插头

Isopimpinellin

发表于2024年10月18日由上海金畔生物科技有限公司

Isopimpinellin 纯度: 99.69%

Isopimpinellin 是从Pimpinella saxifrage 根部分离得到的一种具有口服活性的化合物。Isopimpinellin 通过7,12-dimethylbenz[a]anthracene.阻断 DNA加合物的形成和皮肤肿瘤的发生。Isopimpinellin 具有抗利什曼病的活性。

Isopimpinellin Chemical Structure

CAS No. : 482-27-9

规格	价格	是否有货
5 mg	￥700	In-stock
10 mg	￥1200	In-stock
20 mg	￥2000	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

Isopimpinellin 相关产品

•相关化合物库:

Natural Product Library Plus
Bioactive Compound Library Plus
Anti-Infection Compound Library
Cell Cycle/DNA Damage Compound Library
Immunology/Inflammation Compound Library
Natural Product Library
Anti-Cancer Compound Library
Anti-Aging Compound Library
Traditional Chinese Medicine Monomer Library
Antiparasitic Compound library
Food-Sourced Compound Library

生物活性

Isopimpinellin, an orally active compound isolated from the roots of Pimpinella saxifrage. Isopimpinellin blocks DNA adduct formation and skin tumor initiation by 7,12-dimethylbenz[a]anthracene. Isopimpinellin possesses anti-leishmania effect^[1].

体内研究
(In Vivo)

Isopimpinellin (oral gavage, 35-150 mg/kg) inhibits B[a]P-DNA adduct formation and DMBA–DNA adduct formation in SENCAR mice with skin tumor^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SENCAR mice (7-9 weeks of age) were fed AIN-76A semi-purified diet (Dyets, Bethlehem, PA) for 2 weeks prior to and during the study^[1].
Dosage:	35–150 mg/kg.
Administration:	Oral gavage, suspended in 0.1 mL corn oil at 24 h and 2 h prior to topical treatment with [3H]B[a]P (200 nmol, 1 Ci/mmol) or [3H]DMBA (10 nmol, 10 Ci/mmol) (each in 0.2 mL acetone).
Result:	Significantly inhibited B[a]P-DNA adduct formation by 37 and 26%, respectively. Isopimpinellin (35, 70 and 150 mg/kg) blocked DMBA–DNA adduct formation by 23, 56 and 69%, respectively

分子量

246.22

Formula

C₁₃H₁₀O₅

CAS 号

482-27-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

DMSO : 50 mg/mL (203.07 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.0614 mL	20.3070 mL	40.6141 mL
5 mM	0.8123 mL	4.0614 mL	8.1228 mL
10 mM	0.4061 mL	2.0307 mL	4.0614 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: 2.5 mg/mL (10.15 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (10.15 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (10.15 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (10.15 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

参考文献

[1]. Kleiner HE, et al. Oral administration of the citrus coumarin, isopimpinellin, blocks DNA adduct formation and skin tumor initiation by 7,12-dimethylbenz[a]anthracene in SENCAR mice. Carcinogenesis. 2002 Oct;23(10):1667-75.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Pictilisib(Synonyms: GDC-0941)

发表于2024年10月18日由上海金畔生物科技有限公司

Pictilisib (Synonyms: GDC-0941) 纯度: 99.80%

Pictilisib (GDC-0941) 是有效的 PI3Kα/δ 抑制剂，IC₅₀为 3 nM；对110β (11倍) 和 p110γ (25倍) 具有适度的选择性。

Pictilisib Chemical Structure

CAS No. : 957054-30-7

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥735	In-stock
5 mg	￥650	In-stock
10 mg	￥850	In-stock
50 mg	￥2000	In-stock
100 mg	￥3200	In-stock
200 mg	￥4500	In-stock
500 mg		询价
1 g		询价

* Please select Quantity before adding items.

Pictilisib 相关产品

•相关化合物库:

Drug Repurposing Compound Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Kinase Inhibitor Library
PI3K/Akt/mTOR Compound Library
Stem Cell Signaling Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Autophagy Compound Library
Anti-Aging Compound Library
Drug Repurposing Compound Library
Differentiation Inducing Compound Library
Oxygen Sensing Compound Library
Glycolysis Compound Library
Cytoskeleton Compound Library
Chemical Probe Library
Anti-Breast Cancer Compound Library
Anti-Lung Cancer Compound Library
Anti-Pancreatic Cancer Compound Library
Anti-Blood Cancer Compound Library
Anti-Cancer Metabolism Compound Library
Angiogenesis Related Compound Library
Glucose Metabolism Compound Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC₅₀ of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

IC₅₀ & Target^[5]

p110α

3 nM (IC₅₀)

p110β

33 nM (IC₅₀)

p110δ

3 nM (IC₅₀)

p110γ

75 nM (IC₅₀)

p110α-H1047R

3 nM (IC₅₀)

p110α-E545K

3 nM (IC₅₀)

DNA-PK

1.23 μM (IC₅₀)

mTOR

0.58 μM (Ki)

Autophagy

体外研究
(In Vitro)

Pictilisib (GDC-0941) and RP-56976 reduce tumor cell viability by 80% or greater in the breast cancer cell lines than single-agent treatment. GDC-0941 inhibits Akt phosphorylation and downstream targets of Akt signaling such as pPRAS40 and pS6 in Hs578T1.2 (PI3Kα wild-type), MCF7-neo/HER2 (PI3Kα-mutant), and MX-1 (PTEN-null) tumor models. Pictilisib (GDC-0941) decreases the time of RP-56976-induced mitotic arrest prior to apoptosis^[1]. Pictilisib (GDC-0941) shows a high efficacy of antitumor activity in two ZD1839-resistant non-small cell lung cancer (NSCLC) cell lines, A549 and H460. Pictilisib (GDC-0941) is highly efficacious in combination with U0126 in inducing cell growth inhibition, G0-G1 arrest and cell apoptosis. H460 cells with activating mutations of PIK3CA are relatively more sensitive to Pictilisib (GDC-0941) than A549 cells with wild-type PIK3CA^[3]. Pictilisib (GDC-0941) reduces PI3K pathway activity in both cell lines, illustrated by decreased pAK. Pictilisib (GDC-0941) significantly reduces secreted VEGF detected in the medium after hypoxic/anoxic exposure in all cells^[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Pictilisib (GDC-0941) (150 mg/kg, p.o.) leads to tumor stasis in MCF7-neo/HER2-bearing animals model. Pictilisib (GDC-0941) and RP-56976 result in tumor regressions during the treatment period leading to enhanced antitumor responses^[1]. Tumours in the Pictilisib (GDC-0941)-treated mice show a marked non-linear shrinkage, and when the Pictilisib (GDC-0941) treatment ceased, the tumours in the test cohort mice grow again^[2]. Pictilisib (GDC-0941) (25 or 50 mg/kg) reduces tumor growth and PI3K and HIF-1 pathway activity in eGFP-FTC133 tumor-bearing mice^[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

513.64

Formula

C₂₃H₂₇N₇O₃S₂

CAS 号

957054-30-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 100 mg/mL (194.69 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9469 mL	9.7344 mL	19.4689 mL
5 mM	0.3894 mL	1.9469 mL	3.8938 mL
10 mM	0.1947 mL	0.9734 mL	1.9469 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 0.5% MC 0.5% Tween-80

Solubility: 5 mg/mL (9.73 mM); Suspened solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.87 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (4.87 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (4.87 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: 2.5 mg/mL (4.87 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (4.87 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Wallin JJ, et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of RP-56976 in human breast cancer models by increasing cell death in vitro and in vivo.Clin Cancer Res. 2012 Jul 15;18(14):3901-11. Epub 2012 May 14.

[2]. Wullschleger S, et al. Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma.Anticancer Res. 2012 Feb;32(2):415-20.

[3]. Zou ZQ, et al. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.Mol Med Report. 2012 Feb;5(2):503-8.

[4]. Burrows N, et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.J Clin Endocrinol Metab. 2011 Dec;96(12):E1934-43. Epub 2011 Oct

[5]. Folkes AJ, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem. 2008 Sep 25;51(18):5522-32.

[6]. Ni J, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov. 2012 May;2(5):425-33.

[7]. Cheng H, et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res. 2014 Jan 1;74(1):15-23.

Cell Assay ^[1]	Cells are treated at EC₅₀ concentrations of Pictilisib (GDC-0941), RP-56976, or both for 4 or 24 hours and lysed in 1×Cell Extraction Buffer supplemented with protease inhibitors and Phosphatase Inhibitor Cocktails 1 and 2. Protein concentrations are determined using the Pierce BCA Protein Assay Kit. For immunoblots, equal amounts of protein are separated by electrophoresis through NuPAGE Bis-Tris 10% gradient gels, transferred onto polyvinylidene difluoride membranes using the Criterion system, and probed with monospecific primary antibodies. Specific antigen-antibody interactions are detected with IRDye 680 or IRDye 800 infrared secondary antibodies using a LI-COR imaging system. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Female nu/nu mice are inoculated subcutaneously with MCF7-neo/HER2 or MX-1 breast cancer cells. When tumors reach a mean volume of 200 to 250 mm³, animals are size-matched and distributed into groups consisting of 10 animals per group. RP-56976 formulated in 3% EtOH, 97% saline is administered intravenously once weekly. Pictilisib (GDC-0941), formulated in MCT (0.5% methylcellulose, 0.2% Tween-80) is dosed orally and daily. MAXF1162 is an HER2+/ER+/PR+ patient-derived breast cancer tumor xenograft model established by directly implanting tumors subcutaneously from patient to NMRI nu/nu mice. Tumor volume is calculated. Tumor sizes are recorded twice weekly over the course of a study. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Wallin JJ, et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of RP-56976 in human breast cancer models by increasing cell death in vitro and in vivo.Clin Cancer Res. 2012 Jul 15;18(14):3901-11. Epub 2012 May 14. [2]. Wullschleger S, et al. Quantitative MRI establishes the efficacy of PI3K inhibitor (GDC-0941) multi-treatments in PTEN-deficient mice lymphoma.Anticancer Res. 2012 Feb;32(2):415-20. [3]. Zou ZQ, et al. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.Mol Med Report. 2012 Feb;5(2):503-8. [4]. Burrows N, et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.J Clin Endocrinol Metab. 2011 Dec;96(12):E1934-43. Epub 2011 Oct [5]. Folkes AJ, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem. 2008 Sep 25;51(18):5522-32. [6]. Ni J, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov. 2012 May;2(5):425-33. [7]. Cheng H, et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res. 2014 Jan 1;74(1):15-23.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Prinaberel(Synonyms: 普林贝瑞; ERB-041)

发表于2024年10月18日由上海金畔生物科技有限公司

Prinaberel (Synonyms: 普林贝瑞; ERB-041) 纯度: 98.62%

Prinaberel (ERB-041) 是一种有效的选择性雌激素受体 β (ERβ) 激动剂，对人，大鼠和小鼠 ERβ 的 IC₅₀ 分别为 5.4、3.1 和 3.7 nM。 Prinaberel 对 ERβ 的选择性是 ERα 的 200 倍以上。Prinaberel是有效的皮肤癌化学预防剂，可通过抑制 WNT/β-catenin 信号通路发挥作用。Prinaberel 诱导卵巢癌细胞凋亡 (apoptosis)。

Prinaberel Chemical Structure

CAS No. : 524684-52-4

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥1485	In-stock
10 mg	￥1350	In-stock
50 mg	￥5400	In-stock
100 mg		询价
200 mg		询价

* Please select Quantity before adding items.

Prinaberel 相关产品

•相关化合物库:

Drug Repurposing Compound Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
Apoptosis Compound Library
Stem Cell Signaling Compound Library
Wnt/Hedgehog/Notch Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Anti-Aging Compound Library
Drug Repurposing Compound Library
Differentiation Inducing Compound Library
Anti-COVID-19 Compound Library
Cytoskeleton Compound Library
Neuroprotective Compound Library
Anti-Breast Cancer Compound Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

Prinaberel (ERB-041) is a potent and selective estrogen receptor (ER) β agonist with IC₅₀s of 5.4, 3.1 and 3.7 nM for human, rat and mouse ERβ, respectively. Prinaberel displays >200-fold selectivity for ERβ over ERα. Prinaberel is a potent skin cancer chemopreventive agent that acts by dampening the WNT/β-catenin signaling pathway. Prinaberel induces ovarian cancer apoptosis^[1]^[2]^[3].

IC₅₀ & Target

hERβ

5.4 nM (IC₅₀)

rat ERβ

3.1 nM (IC₅₀)

mouse ERβ

3.7 nM (IC₅₀)

hERα

1200 nM (IC₅₀)

mouse ERα

750 nM (IC₅₀)

rat ERα

620 nM (IC₅₀)

体外研究
(In Vitro)

Prinaberel (ERB-041) (0-60 µM; 24 hours) treatment of human SCC cells induces cell differentiation, cell cycle arrest and reduces colony formation^[2].
Prinaberel shows a marked reduction in the expression of inflammation regulatory proteins such as p-NFκBp65, iNOS and COX-2 in A431 cells. Prinaberel diminishes phosphorylated-PI3K and -AKT, which is associated with the enhancement in E-cadherin expression and reduction in migration of A431 cells^[2].
Prinaberel (0.01-10 µM) inhibits cell proliferation in a dose- and time-dependent manner^[3].
Prinaberel (10 µM; 48 hours) promotes ovarian cancer (SKOV-3 cells) apoptosis^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	A431 cells
Concentration:	0, 20, 40 and 60 µM
Incubation Time:	24 hours
Result:	Reduction in the expression of G1 cyclins (D1, D2 and D3) and CDK4.

Cell Proliferation Assay^[3]

Cell Line:	SKOV-3, A2780CP or OVCAR-3 cells
Concentration:	0.01, 0.1 and 10 µM
Incubation Time:	24-48 hours
Result:	Showed significantly inhibitory effect on cell proliferation.

体内研究
(In Vivo)

Prinaberel (2mg/mouse; topically; 30 min prior to UVB irradiation for 30 weeks) suppresses development of squamous cell carcinoma in SKH-1 hairless mice^[2].
Prinaberel reduces proliferation and angiogenesis and induces apoptosis in UVB-induced skin tumors. Prinaberel suppresses pro-inflammatory signaling pathway in UVB-induced skin tumors. Prinaberel diminished tumor invasiveness via PI3K-AKT pathway and WNT signaling^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six- to eight-weeks-old SKH-1 hairless female mice^[2]
Dosage:	2 mg/mouse in 200µl ethanol
Administration:	Topically; 30 min prior to UVB (180mJ/cm2) irradiation for 30 weeks
Result:	Diminished UVB-induced skin tumor development in SKH-1 hairless mice.

Clinical Trial

分子量

271.24

Formula

C₁₅H₁₀FNO₃

CAS 号

524684-52-4

中文名称

普林贝瑞

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 40 mg/mL (147.47 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.6868 mL	18.4339 mL	36.8677 mL
5 mM	0.7374 mL	3.6868 mL	7.3735 mL
10 mM	0.3687 mL	1.8434 mL	3.6868 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 5 mg/mL (18.43 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (18.43 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 5 mg/mL (18.43 mM); Suspended solution; Need ultrasonic

此方案可获得 5 mg/mL (18.43 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 5 mg/mL (18.43 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (18.43 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Malamas MS, et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004;47(21):5021-5040.

[2]. Chaudhary SC, et al. Erb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014;7(2):186-198.

[3]. Chan KKL, et al. Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer. Cancer Cell Int. 2018;18:65. Published 2018 May 1.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

英国Electrothermal V型电加热套EMV1000,EMV5000

发表于2024年10月18日由上海金畔生物科技有限公司

【简单介绍】

英国Electrothermal V型电加热套EMV1000,EMV5000可以容纳60°锥型漏斗、梨形和圆底烧瓶。多种尺寸的烧瓶和漏斗都可容纳，更多灵活性。有一个不锈钢保护屏覆盖在加热元件上方，保护您在液体溅射和烧瓶破裂时免受电击。
！

【详细说明】

英国Electrothermal V型电加热套EMV1000,EMV5000

产品描述：

英国Electrothermal V型电加热套EMV1000,EMV5000可以容纳60°锥型漏斗、梨形和圆底烧瓶。多种尺寸的烧瓶和漏斗都可容纳，更多灵活性。有一个不锈钢保护屏覆盖在加热元件上方，保护您在液体溅射和烧瓶破裂时免受电击。

EMV系列 V型电加热套的主要特点:
底座开口，可容纳60°锥型漏斗、梨形和圆底烧瓶
可容纳大型的烧瓶/漏斗，容量在10ml-5L之间
盘绕的加热元件悬挂在一个隔热盒中，提供佳的热传递和支撑
“Cool-to-the-touch”凉外壳技术
加热元件温度可达450℃
内置功率调节器
配有电源和加热指示灯
可更换独立加热盘
化学防腐聚丙烯外壳
接地保护屏和双保险管等更多安全措施
适合13cm直径支撑杆的固定夹（但不包含支撑杆）

技术指标

EMV/ EMX 型号	EMV0050, EMV0100, EMV0250	EMV1000, EMX1000	EMV5000, EMX5000
烧瓶/漏斗容量	10 – 250ml	500 – 1000ml	2000- 5000ml
材质	聚丙烯外壳	聚丙烯外壳	聚丙烯外壳
大元件温度	450°C	450°C	450°C
尺寸 (d x w x h), mm	260 x 175 x 127	310 x 238 x 145	400 x 350 x 190
运输重量, kg	0.78	2.76	5.96

订货信息

型号	容量	电源
EMV0050/CE	10 to 50ml	230V 50/60Hz, 60W
EMV0050/CEX1	10 to 50ml	115V 50/60Hz, 70W
EMV0050/CEX6*	10 to 50ml	230V 50/60Hz, 60W
EMV0250/CE	100 to 250ml	230V 50/60Hz, 150W
EMV0250/CEX1	100 to 250ml	115V 50/60Hz, 150W
EMV0250/CEX6*	100 to 250ml	230V 50/60Hz, 150W
EMV1000/CE	500 to 1000ml	230V 50/60Hz, 300W
EMV1000/CEX1	500 to 1000ml	115V 50/60Hz, 300W
EMV1000/CEX6*	500 to 1000ml	230V 50/60Hz, 300W
EMV5000/CE	2000 to 5000ml	230V 50/60Hz, 800W
EMV5000/CEX1	2000 to 5000ml	115V 50/60Hz, 800W
EMV5000/CEX6*	2000 to 5000ml	230V 50/60Hz, 800W

*附带EU欧洲插头

上海沛欧红外石英消化炉SKD-48S2

发表于2024年10月18日由上海金畔生物科技有限公司

上海沛欧红外石英消化炉SKD-48S2

品牌沛欧|PEIOU

型号 SKD-48S2

商品详情

专利号：ZL.2011.2.0531950.9

红外石英消化炉SKD-48S2特点

1、加热体（模块）采用红外加热，石英管辐射，耐强酸强碱、防爆裂，寿命长

2、红外石英消化炉SKD-48S2炉孔温度和速率连续可调，升温速度快且杜绝挂壁

3、消化管受热面积大、温差小，样品消化一致性好

4、仪器具有过流保护和漏电保护

5、采用双开关，电源和加热体单独控制，便于安全参数设置

6、仪器标配弯颈漏斗，有利于硫酸等冷凝液体的回流，有利于消化的彻底。

如何选择消化炉？

消化炉在蛋白质检测中起到了重要作用，如何选择一台合适的消化炉？

消化炉指标要注意以下几点：

*要有效地温度控制。要使得样品硝化能需要温度进行，如果有消化炉程序升温控制，就能有效满足样品的需要。

*要很好的保温措施。如果保温材料势单力薄，必造成温度不稳定，仪器较厚的保温层是温度是温度稳定的需要。故保温材料的厚度和材质是一个重要的指标、

*加热体和热载体的选择，可以可以根据用户的需要选择不同热载体。下面我们来讨论加热体和热载体的选择。现在加热主要有二种方式比较好的

#红外加热，靠热辐射来加热样品。特点是：升温快，热惯性小，温控准确。一般应用于有高要求样品的硝化。例如：有较高较快的升温和降温要求。程序升温可以使用户根据自己样品的特点来选择升温曲线，或选择分段式的升温，更有利于样品的消化。从而杜绝样品的挂壁现象、进而使得样品硝化效率的大大提高

#铝锭加热，靠铝锭传热给样品。特点：升温较慢，热惯性较大，温度较稳定，还由于铝锭的良好的热传导性，每个样品孔间的温度一致性好。广泛应用于消化炉的热载体，但也要注意：一片薄薄的铝锭也不能保持温度的恒定，所以选择铝锭消化炉，铝锭厚度也是一个考察指标。

#石墨加热，靠石墨传导给样品量。特点：热惯性大，升温较慢，由于石墨热传导性较差（相比较铝锭），使得样品孔间温度不均匀，容易造成样品间硝化时间拉大。但是由于石墨成本较低，所以石墨消化炉便宜，对部分低端用户有一定的吸引力。

另外要注意消化炉的保护功能：温度稳定均一保护，过流、漏电和短路保护。

一、概述：
红外石英消化炉SKD-48S2可用于农业、林业、环保、地质、化工、食品等部门以及高等院校、科研部门对植株、种子、饲料、食品、土壤、矿石等硝化
二、红外石英消化炉SKD-48S2技术指标：
红外石英消化炉
型号：SKD-48S2

*控制方式：单片机 (定时+64阶程序升温）

*加热方式：红外石英加热管
炉孔数量：48孔
*控温范围：室温-680℃

升温速度：22分钟（400℃预热）
温度波动：+-1

双保温层：硅酸棉和空气双层保温
* 功率：2.2KW

仪器机箱尺寸：655*340*210mm

消化管尺寸：25*3

三、红外石英消化炉SKD-48S2特点：

1 、温度可控，样品还原性好。

2、加热体（模块）采用红外加热，石英管辐射，耐强酸强碱、防爆裂，寿命长，符合CE标准

3、炉孔温度和升温速率可调，升温速度快且杜绝挂壁

4、消化管受热面积大、温差小，样品消化一致性好，热效率高

5、仪器具有过流保护和漏电保护

6、采用双开关，电源和加热单独控制，便于安全参数设置，节约能源。

7、采用新一代数显控温仪，PID控制技术，控温精度高

8、仪器标配不锈钢排污罩，使消化过程中产生的S02等有害气体，通过排污罩经抽吸泵排走，有效地抑制有害气体的外逸，消化管，消化架，冷却架。

9、样品防爆器（选配）

Lithospermoside(Synonyms: 紫草氰苷; Griffonin)

发表于2024年10月18日由上海金畔生物科技有限公司

Lithospermoside (Synonyms: 紫草氰苷; Griffonin) 纯度: 99.48%

Lithospermoside (Griffonin) 是从 Ochna schweinfurthiana F. Hoffm 茎皮中分离出的一种天然产物。

Lithospermoside Chemical Structure

CAS No. : 63492-69-3

规格	价格	是否有货
5 mg	￥600	In-stock
10 mg	￥1000	In-stock
20 mg	￥1800	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

Lithospermoside 相关产品

•相关化合物库:

Covalent Screening Library Plus
Natural Product Library Plus
Bioactive Compound Library Plus
Natural Product Library
Anti-Cancer Compound Library
Covalent Screening Library
Glycoside Compound Library
Traditional Chinese Medicine Monomer Library

生物活性

Lithospermoside (Griffonin) is a nature product isolated from the stem bark of Ochna schweinfurthiana F. Hoffm^[1].

分子量

329.30

Formula

C₁₄H₁₉NO₈

CAS 号

63492-69-3

中文名称

紫草氰苷

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

H₂O : 31.25 mg/mL (94.90 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0367 mL	15.1837 mL	30.3674 mL
5 mM	0.6073 mL	3.0367 mL	6.0735 mL
10 mM	0.3037 mL	1.5184 mL	3.0367 mL

参考文献

[1]. Ndongo JT, et al. Cytotoxic flavonoids and other constituents from the stem bark of Ochna schweinfurthiana. Nat Prod Res. 2015;29(17):1684-7.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

LGK974(Synonyms: WNT974)

发表于2024年10月18日由上海金畔生物科技有限公司

LGK974 (Synonyms: WNT974) 纯度: 99.79%

LGK974 (WNT974) 是一种有效的，具有口服活性的特异性 Porcupine (PORCN) 抑制剂，IC₅₀ 为 0.1 nM。

LGK974 Chemical Structure

CAS No. : 1243244-14-5

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥1134	In-stock
2 mg	￥800	In-stock
5 mg	￥1300	In-stock
10 mg	￥2200	In-stock
50 mg	￥6500	In-stock
100 mg	￥11160	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

LGK974 相关产品

•相关化合物库:

Drug Repurposing Compound Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
Stem Cell Signaling Compound Library
Wnt/Hedgehog/Notch Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Anti-Aging Compound Library
Drug Repurposing Compound Library
Orally Active Compound Library

生物活性

LGK974 (WNT974) is an orally bioavailable and specific Porcupine (PORCN) inhibitor with an IC₅₀ of 0.1 nM^[1].

IC₅₀ & Target

Porcupine^[1]

体外研究
(In Vitro)

LGK974 effectively displaces [³H]-GNF-1331 with an IC₅₀ of 1 nM in the PORCN radioligand binding assay. LGK974 potently reduces Wnt-dependent AXIN2 mRNA levels in HN30 cells with an IC₅₀ of 0.3 nM^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

LGK974, a drug that targets Porcupine, a Wnt-specific acyltransferase. LGK974 potently inhibits Wnt signaling, has strong efficacy in rodent tumor models, and is well-tolerated. Toxicology studies are performed on nontumor bearing rats at 3 and 20 mg/kg. At the efficacious dose of 3 mg/kg per day for 14 d, LGK974 is well-tolerated without abnormal histopathological findings in Wnt-dependent tissues, including the intestine, stomach, and skin. When rats are administrated a very high dose of 20 mg/kg per day for 14 d, loss of intestinal epithelium is observed, consistent with the concept that Wnt is required for intestinal tissue homeostasis^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

396.44

Formula

C₂₃H₂₀N₆O

CAS 号

1243244-14-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 32 mg/mL (80.72 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5224 mL	12.6122 mL	25.2245 mL
5 mM	0.5045 mL	2.5224 mL	5.0449 mL
10 mM	0.2522 mL	1.2612 mL	2.5224 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (6.31 mM); Suspended solution; Need ultrasonic and warming

此方案可获得 2.5 mg/mL (6.31 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.31 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.31 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Liu J, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9.

[2]. Tammela T, et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 May 18;545(7654):355-359.

Cell Assay ^[1]	HN30 cells and UMSCC cells are used. For TaqMan assay, 2×10⁶ cells per well are plated into six-well cell culture plates and treated with or without LGK974 in amultipoint dose-response. RNA samples are collected after 48 h. For colony formation assays, 2×10³ cells per well are plated into six-well cell culture plates with or without compound treatment. Cells are stained with crystal violet 1 wk later^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice and Rats^[1] Nude mice (or nude rats) bearing the mouse mammary tumor virus-Wnt1, HN30, or SNU1076 tumors are randomized according to tumor volume. LGK974 is formulated in 10% (vol/vol) citrate buffer (pH 2.8)/90% (vol/vol) citrate buffer (pH 3.0) or 0.5% MC/0.5% Tween 80 and administered by oral gavage at a dosing volume of 10 μL/g animal body weight. Body weight is monitored daily, and tumor sizes are assessed three times per week after the tumors are palpable. Tumor sizes are determined by using caliper measurements. Tumor volumes are calculated with a formula (length×width×height)/2. The plasma concentrations and exposures of LGK974 in the tumor-bearing nude mice (n=2 per dosing group) are determined on day 14. Blood samples (50 μL) are collected by serial retroorbital sampling at 1, 3, 7, 16, and 24 h postdose. The blood samples are centrifuged, and plasma is separated and frozen until analysis by liquid chromatography/MS/MS. For tolerability studies, LGK974 is administrated to nontumor-bearing Wistar rats one time per day by oral gavage at 3 or 20 mg/kg per day. Necropsies are performed at the end of the study. Tissues are fixed in 10% (vol/vol) neutralbuffered formalin, sectioned, and subjected to H&E staining. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Liu J, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. [2]. Tammela T, et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 May 18;545(7654):355-359.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

ON123300

发表于2024年10月18日由上海金畔生物科技有限公司

ON123300 纯度: 99.34%

ON123300 是一种强效的，可透过血脑屏障的多激酶抑制剂，可抑制 CDK4 (IC₅₀=3.9 nM），Ark5 (IC₅₀=5 nM)，PDGFRβ (IC₅₀=26 nM)，FGFR1 (IC₅₀=26 nM)，RET (IC₅₀=9.2 nM) 和 FYN (IC₅₀=11 nM)。ON123300 在脑肿瘤中抑制 Akt 磷酸化及激活 Erk。ON123300 抑制 CDK6，IC₅₀ 为 9.82 nM。

ON123300 Chemical Structure

CAS No. : 1357470-29-1

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥1134	In-stock
2 mg	￥800	In-stock
5 mg	￥1200	In-stock
10 mg	￥1800	In-stock
50 mg	￥6600	In-stock
100 mg	￥9950	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

ON123300 相关产品

•相关化合物库:

Covalent Screening Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
Cell Cycle/DNA Damage Compound Library
Epigenetics Compound Library
Kinase Inhibitor Library
PI3K/Akt/mTOR Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Anti-Aging Compound Library
Covalent Screening Library
Antioxidants Compound Library
Oxygen Sensing Compound Library
Glycolysis Compound Library
Cytoskeleton Compound Library
Anti-Breast Cancer Compound Library
Anti-Pancreatic Cancer Compound Library
Anti-Blood Cancer Compound Library
Anti-Cancer Metabolism Compound Library
Lipid Metabolism Compound Library
Glucose Metabolism Compound Library

生物活性

ON123300, a strong and brain-penetrant^[1] multi-kinase inhibitor, inhibits CDK4 (IC₅₀=3.9 nM), Ark5 (IC₅₀=5 nM), PDGFRβ (IC₅₀=26 nM), FGFR1 (IC₅₀=26 nM), RET (IC₅₀=9.2 nM), and FYN (IC₅₀=11 nM). Single agent ON123300 causes a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors^[2]. ON123300 inhibits CDK6 with an IC₅₀ of 9.82 nM^[3].

IC₅₀ & Target^[2]^[3]

Cdk4/cyclin D1

3.9 nM (IC₅₀)

ARK5

5 nM (IC₅₀)

CDK6/cyclinD1

9.82 nM (IC₅₀)

RET

9.2 nM (IC₅₀)

FYN

11 nM (IC₅₀)

FGFR1

26 nM (IC₅₀)

PDGFRβ

26 nM (IC₅₀)

PI3K-δ

144 nM (IC₅₀)

体外研究
(In Vitro)

ON123300 inhibits U87 glioma cell proliferation with an IC₅₀ of 3.4±0.1 μM^[2]. ON123300 (1 and 10 μM) inhibits cell proliferation in a panel of 11 glioma models including a patient-derived model (GBM10)^[2].
ON123300 (6.3 μM; 1 h) reduces phosphorylation of Akt and its downstream signaling components, P70S6K, 40S rpS6 and Rb S780, yet ON123300 induces Erk activation in U87 cells; both in a dose- and time-dependent manner^[2]. ON123300 inhibits PI3Kδ with the IC₅₀ of 144nM^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[2]

Cell Line:	U87 glioma cells
Concentration:	0, 4, 8, 12, 16 μM
Incubation Time:	72 hour
Result:	Had an IC₅₀ equal to 3.4±0.1 μM.

Western Blot Analysis^[2]

Cell Line:	U87 cells
Concentration:	6.3 μM
Incubation Time:	1 h
Result:	Inhibited phosphorylation of Akt (at S473 site) and its downstream signaling components, P70S6K, 40S ribosomal protein S6 (rpS6) and Rb S780 (decreased to 40.1%; 31.8 %; 60.5%; 54.5% relatively to control), yet increased p-Erk (increased to 120% relative to control).

体内研究
(In Vivo)

ON123300 decreases p-Akt expression and increases p-Erk activity in brain tumors upon administration at both IV doses of 5 mg/kg and 25 mg/kg in U87 brain tumor-bearing mouse. The half-life (T_1/2) is 1.5 h for 5 mg/kg and 25 mg/kg in plasma^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NIH Swiss nude mice bearing U87 glioma model^[2].
Dosage:	5 mg/kg or 25 mg/kg
Administration:	IV bolus at a dose of either 5 mg/kg or 25 mg/kg via a tail vein.
Result:	The p-Akt rapidly declined and reached nadir values of 73% and 60% of control within 30 min after 5 mg/kg and 25 mg/kg dose levels, respectively.

Clinical Trial

分子量

429.52

Formula

C₂₄H₂₇N₇O

CAS 号

1357470-29-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 16.67 mg/mL (38.81 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3282 mL	11.6409 mL	23.2818 mL
5 mM	0.4656 mL	2.3282 mL	4.6564 mL
10 mM	0.2328 mL	1.1641 mL	2.3282 mL

参考文献

[1]. Hua Lv, et al. Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J. 2013 Jan;15(1):250-7.

[2]. Xiaoping Zhang, et al. Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models. Mol Cancer Ther. 2014 May;13(5):1105-16.

[3]. S K A Divakar, et al. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas. Leukemia. 2016 Jan;30(1):86-93.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

英国Electrothermal V-型和防溅保护电加热套EMV和EMX（塑料外壳）

发表于2024年10月18日由上海金畔生物科技有限公司

【简单介绍】

英国Electrothermal V-型和防溅保护电加热套EMV和EMX（塑料外壳）可以容纳60°锥型漏斗、梨形和圆底烧瓶。多种尺寸的烧瓶和漏斗都可容纳，更多灵活性。
！

【详细说明】

英国Electrothermal V-型和防溅保护电加热套EMV和EMX（塑料外壳）

产品描述：

英国Electrothermal V-型和防溅保护电加热套EMV和EMX（塑料外壳）可以容纳60°锥型漏斗、梨形和圆底烧瓶。多种尺寸的烧瓶和漏斗都可容纳，更多灵活性。

所有EMV系列型号都有一个不锈钢保护屏覆盖在加热元件上方，保护您在液体溅射和烧瓶破裂时免受电击。所有EMX系列型号都有一个不锈钢保护衬板，增加液体溅射时的电器和机械保护，并且容易清洁。

EMX系列防溅保护电加热套的主要特点：
底座开口，可容纳60°锥型漏斗、梨形和圆底烧瓶
可容纳大型的烧瓶/漏斗，容量在500ml-5L之间
盘绕的加热元件悬挂在一个隔热盒中，提供佳的热传递和支撑
“Cool-to-the-touch”凉外壳技术
加热元件温度可达450℃
内置功率调节器
配有电源和加热指示灯
可更换独立加热盘
化学防腐聚丙烯外壳
双保险管更安全
接地不锈钢衬增加液体溅射时的安全保护
适合13cm直径支撑杆的固定夹（但不包含支撑杆）
质量保证: 一年零部件
认证: CE

技术指标

EMV/ EMX 型号	EMV0050, EMV0100, EMV0250	EMV1000, EMX1000	EMV5000, EMX5000
烧瓶/漏斗容量	10 – 250ml	500 – 1000ml	2000- 5000ml
材质	聚丙烯外壳	聚丙烯外壳	聚丙烯外壳
大元件温度	450°C	450°C	450°C
尺寸 (d x w x h), mm	260 x 175 x 127	310 x 238 x 145	400 x 350 x 190
运输重量, kg	0.78	2.76	5.96

EMV系列订货信息

型号	容量	电源
EMV0050/CE	10 to 50ml	230V 50/60Hz, 60W
EMV0050/CEX1	10 to 50ml	115V 50/60Hz, 70W
EMV0050/CEX6*	10 to 50ml	230V 50/60Hz, 60W
EMV0250/CE	100 to 250ml	230V 50/60Hz, 150W
EMV0250/CEX1	100 to 250ml	115V 50/60Hz, 150W
EMV0250/CEX6*	100 to 250ml	230V 50/60Hz, 150W
EMV1000/CE	500 to 1000ml	230V 50/60Hz, 300W
EMV1000/CEX1	500 to 1000ml	115V 50/60Hz, 300W
EMV1000/CEX6*	500 to 1000ml	230V 50/60Hz, 300W
EMV5000/CE	2000 to 5000ml	230V 50/60Hz, 800W
EMV5000/CEX1	2000 to 5000ml	115V 50/60Hz, 800W
EMV5000/CEX6*	2000 to 5000ml	230V 50/60Hz, 800W

EMX系列订货信息

型号	容量	电源
EMX1000/CE	500 to 1000ml	230V 50/60Hz, 245W
EMX1000/CEX1	500 to 1000ml	115V 50/60Hz, 240W
EMX1000/CEX6*	500 to 1000ml	230V 50/60Hz, 245W
EMX5000/CE	2000 to 5000ml	230V 50/60Hz, 600W
EMX5000/CEX1	2000 to 5000ml	115V 50/60Hz, 600W
EMX5000/CEX6*	2000 to 5000ml	230V 50/60Hz, 600W

*附带EU欧洲插头

Irisolidone(Synonyms: 尼泊尔鸢尾异黄酮)

发表于2024年10月18日由上海金畔生物科技有限公司

Irisolidone (Synonyms: 尼泊尔鸢尾异黄酮) 纯度: 99.66%

Irisolidone 是葛根花中的主要的异黄酮。Irisolidone 具有较强的保肝活性。Irisolidone 对阴离子通道 VRAC 具有高效阻断作用 (IC₅₀=9.8 μM)。

Irisolidone Chemical Structure

CAS No. : 2345-17-7

规格	价格	是否有货
1 mg	￥1300	In-stock
5 mg	￥2950	In-stock
10 mg	￥4480	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

Irisolidone 相关产品

•相关化合物库:

Natural Product Library Plus
Bioactive Compound Library Plus
Membrane Transporter/Ion Channel Compound Library
Natural Product Library
Anti-Cancer Compound Library
Medicine Food Homology Compound Library
Phenols Library
Traditional Chinese Medicine Monomer Library
Flavonoids Library

生物活性	Irisolidone is a major isoflavone found in Pueraria lobata flowers. Irisolidone exhibits potent hepatoprotective activity. Irisolidone shows the high efficacy for volume-regulated anion channels (VRAC) blockade (IC₅₀=9.8 μM)^[1]^[2]^[3].
体外研究 (In Vitro)	Irisolidone, an isoflavone metabolite, represses JC virus gene expression via inhibition of Sp1 binding in human glial cells^[1]. Irisolidone can inhibit endothelial cell proliferation^[3]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量	314.29
Formula	C₁₇H₁₄O₆
CAS 号	2345-17-7
中文名称	尼泊尔鸢尾异黄酮
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
参考文献	[1]. Kim SY, et al. Irisolidone, an isoflavone metabolite, represses JC virus gene expression via inhibition of Sp1 binding in human glial cells. Biochem Biophys Res Commun. 2006 May 26;344(1):3-8. [2]. Zhang G, et al. Pharmacokinetics of irisolidone and its main metabolites in rat plasma determined by ultra performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Nov 15;1005:23-9. [3]. Xue Y, et al. Natural and synthetic flavonoids, novel blockers of the volume-regulated anion channels, inhibit endothelial cell proliferation. Pflugers Arch. 2018 Oct;470(10):1473-1483.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

BMS-1(Synonyms: PD-1/PD-L1 inhibitor 1)

发表于2024年10月18日由上海金畔生物科技有限公司

BMS-1 (Synonyms: PD-1/PD-L1 inhibitor 1) 纯度: 99.56%

BMS-1 是 PD-1/PD-L1 蛋白质/蛋白质相互作用的抑制剂，IC₅₀ 为 6 到 100 nM。

BMS-1 Chemical Structure

CAS No. : 1675201-83-8

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥1320	In-stock
5 mg	￥1200	In-stock
10 mg	￥1900	In-stock
25 mg	￥3800	In-stock
50 mg	￥5500	In-stock
100 mg	￥8800	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

BMS-1 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Apoptosis Compound Library
Immunology/Inflammation Compound Library
Anti-Cancer Compound Library
Small Molecule Immuno-Oncology Compound Library
Peptidomimetic Library
Anti-Breast Cancer Compound Library
Anti-Lung Cancer Compound Library
Anti-Blood Cancer Compound Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC₅₀ between 6 and 100 nM)^[1]^[2].

IC₅₀ & Target

PD1-PDL1^[1]

体外研究
(In Vitro)

Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity of the co-cultured NK92 cells are reversed by BMS-1^[1]. BMS-1, a small-molecule immune checkpoint inhibitor of PD-1/PD-L1, can be used as a therapeutic strategy for tumor immunotherapy^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	NK cells and HepG2 cells
Concentration:	1 μM
Incubation Time:	3 days
Result:	Disturbed the interaction between PD-1 and PD-L1.

体内研究
(In Vivo)

BMS-1 (500 μg/mL; 100 μL; i.p.) significantly increases the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice with EMT6 cells^[3]
Dosage:	500 μg/mL; 100 μL
Administration:	I.p.
Result:	Increased the survival rates of the mVEGF165b group and mVEGF165b + MUC1 group. mVEGF165b combined with MUC1 results significant retardation of the tumor growth.

分子量

475.58

Formula

C₂₉H₃₃NO₅

CAS 号

1675201-83-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

Methanol : 25 mg/mL (52.57 mM; Need ultrasonic)

DMSO : 17.86 mg/mL (37.55 mM; ultrasonic and warming and heat to 60°C)

DMF : 5 mg/mL (10.51 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1027 mL	10.5135 mL	21.0270 mL
5 mM	0.4205 mL	2.1027 mL	4.2054 mL
10 mM	0.2103 mL	1.0513 mL	2.1027 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 1 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.10 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 1 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.10 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 1 mg/mL (2.10 mM); Clear solution

此方案可获得 ≥ 1 mg/mL (2.10 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4.

[2]. Li K, et al. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019 Mar;27(3):244-256.

[3]. Zhang H, et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019 Apr 3;37(15):2090-2098.

[4]. Mengyuan Li, et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020 Oct;8(2):e000293.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SGI-7079

发表于2024年10月18日由上海金畔生物科技有限公司

SGI-7079 纯度: 99.65%

SGI-7079 是一种 ATP-竞争性 Axl 抑制剂, 显著抑制 SUM149 和 KPL-4 细胞增殖，IC₅₀ 分别为 0.43 和 0.16 μM。

SGI-7079 Chemical Structure

CAS No. : 1239875-86-5

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥952	In-stock
2 mg	￥650	In-stock
5 mg	￥950	In-stock
10 mg	￥1500	In-stock
50 mg	￥5500	In-stock
100 mg	￥7200	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

SGI-7079 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Kinase Inhibitor Library
Protein Tyrosine Kinase Compound Library
Anti-Cancer Compound Library
Targeted Diversity Library

生物活性

SGI-7079 is a potent and ATP-competitive Axl inhibitor, significantly inhibits the proliferation of SUM149 or KPL-4 cells with an IC₅₀ of 0.43 or 0.16 μM, respectively.

分子量

455.53

Formula

C₂₆H₂₆FN₇

CAS 号

1239875-86-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 34 mg/mL (74.64 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1952 mL	10.9762 mL	21.9525 mL
5 mM	0.4390 mL	2.1952 mL	4.3905 mL
10 mM	0.2195 mL	1.0976 mL	2.1952 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.17 mg/mL (4.76 mM); Clear solution

此方案可获得 ≥ 2.17 mg/mL (4.76 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.17 mg/mL (4.76 mM); Clear solution

此方案可获得 ≥ 2.17 mg/mL (4.76 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 21.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Wang X, et al. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res. 2013 Nov 1;73(21):6516-25.

[2]. Byers LA, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 1;19(1):279-90.

[3]. Chenjing Zhu, et al. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

上海沛欧红外石英消化炉SKD-18S2

发表于2024年10月18日由上海金畔生物科技有限公司

上海沛欧红外石英消化炉SKD-18S2

品牌沛欧|PEIOU

型号 SKD-18S2

商品详情

红外石英消化炉SKD-18S2特点

1、红外石英消化炉SKD-18S2加热体（模块）采用红外加热，石英管辐射，耐强酸强碱、防爆裂，寿命长

2、炉孔温度和速率连续可调，升温速度快且杜绝挂壁

3、消化管受热面积大、温差小，样品消化一致性好

4、仪器具有过流保护和漏电保护

5、采用双开关，电源和加热体单独控制，便于安全参数设置

6、仪器标配不锈钢排污罩，使消化过程中产生的SO2等有害气体，通过排污管经抽吸泵排走，有效地抑制有害气体的外逸

如何选择消化炉？

消化炉在蛋白质检测中起到了重要作用，如何选择一台合适的消化炉？

消化炉指标要注意以下几点：

*要有效地温度控制。要使得样品硝化能需要温度进行，如果有消化炉程序升温控制，就能有效满足样品的需要。

*加热体和热载体的选择，可以可以根据用户的需要选择不同热载体。下面我们来讨论加热体和热载体的选择。现在加热主要有二种方式比较好的

另外要注意消化炉的保护功能：温度稳定均一保护，过流、漏电和短路保护。

红外石英消化炉SKD-18S2特点

1、加热体（模块）采用红外加热，石英管辐射，耐强酸强碱、防爆裂，寿命长

2、炉孔温度和速率连续可调，升温速度快且杜绝挂壁

3、消化管受热面积大、温差小，样品消化一致性好

4、仪器具有过流保护和漏电保护

5、采用双开关，电源和加热体单独控制，便于安全参数设置

6、仪器标配不锈钢排污罩，使消化过程中产生的SO2等有害气体，通过排污管经抽吸泵排走，有效地抑制有害气体的外逸

红外石英程序升温18孔消化炉的详细介绍

1.石英结构加热原理

远红外石英加热元件我公司采用珠光乳白石英管配用电热材料，使原件具有优良可靠的远红外辐射特性,通电后,热材料发出的红外光与可见光中97％被乳白管所阻挡吸收使管壁温度升高产生硅氧键分子振动辐射远红外线,这样使97％可见光和近红外光可转为远红外辐射。克服了单纯使用透明石英玻璃带来的透过可见和近红外的弊端,从而有效地使电能转化为远红外线。

2. 红外石英程序升温消化炉特点

远红外石英加热元件是以乳白石英管为红外辐射源, 没有涂层，没有污染，没有有害辐射，化学稳定性好，耐高温, 形状多样，长久使用不变形，热稳定性好，加热温度可行选择。长期使用辐射性能不退变。并且使用寿命长，结构合理，热惯性极小，使用方便。

一、概述：
红外石英消化炉SKD-18S2可用于农业、林业、环保、地质、化工、食品等部门以及高等院校、科研部门对植株、种子、饲料、食品、土壤、矿石等硝化

二、红外石英消化炉SKD-18S2技术指标：
型号：SKD-18S2

*控制方式：单片机 (定时+64阶程序升温）

*加热方式：红外加热，石英辐射
炉孔数量：18孔
*控温范围：室温-680℃

升温速度：12分钟（400℃预热）
温度波动：+-1

双保温层：硅酸棉和空气双层保温
* 功率:1.6KW

仪器机箱尺寸：655*340*210mm

消化管尺寸：25*300mm

三、红外石英消化炉SKD-18S2特点

1、温度可控，样品还原性好。

2、加热体（模块）采用红外加热，石英管辐射，耐强酸强碱、防爆裂，寿命长，符合CE标准

3、炉孔温度和升温速率可调，升温速度快且杜绝挂壁

4、消化管受热面积大、温差小，样品消化一致性好，热效率高

5、仪器具有过流保护和漏电保护

6、采用双开关，电源和加热单独控制，便于安全参数设置，节约能源。

7、采用新一代数显控温仪，PID控制技术，控温精度高

8、仪器标配不锈钢排污罩，使消化过程中产生的S02等有害气体，通过排污罩经抽吸泵排走，有效地抑制有害气体的外逸，消化管，消化架，冷却架。

9、样品防爆器（选配）